Factor V Leiden sounds like it should be rare. A named mutation, a specific spot on a specific gene, discovered in the Dutch city of Leiden in the 1990s — it has the feel of something exotic. It isn't. It's carried by roughly 1 in 20 to 1 in 12 people of European ancestry, which makes it far more common than most of the conditions that get more airtime in genetic testing conversations.
What Factor V Actually Does
Factor V is a protein involved in blood clotting — specifically, it helps clots form when you're injured. Normally, once a clot has done its job, a protein called activated protein C (APC) switches Factor V off, so clotting doesn't run away with itself. The Factor V Leiden mutation changes one amino acid at the exact spot APC needs to grab onto. The result: Factor V gets shut off roughly ten times slower than normal, so it lingers in your bloodstream and the clotting process stays "on" longer than it should.
This doesn't cause clots to form out of nowhere. It raises the odds that, when the usual triggers for a clot show up — a long flight, surgery, pregnancy, certain hormonal medications, prolonged immobility — your body is slower to shut the process down once it starts.
The Actual Risk Numbers
Here's where the picture gets more reassuring than the "clotting mutation" framing suggests. Having one copy (heterozygous) raises your lifetime risk of an abnormal clot from a baseline of roughly 1 in 1,000 per year to somewhere around 3 to 8 in 1,000 per year — a real increase, but still a low absolute number. Having two copies (homozygous, roughly 1 in 5,000 people) raises that risk much more substantially. And critically: most carriers never develop a clot at all. Only around 10% of people with the mutation experience one in their lifetime, and in community-based cohort studies, the risk for carriers under 60 barely differed from non-carriers — the elevated risk shows up much more clearly after age 60.
| Status | Relative clot risk | Approx. population frequency |
|---|---|---|
| No mutation | Baseline (~1 in 1,000/yr) | — |
| Heterozygous (1 copy) | ~4–8× baseline | ~3–8% (European ancestry) |
| Homozygous (2 copies) | Up to ~80× baseline | ~1 in 5,000 |
Where it gets more clinically relevant is in combination with other risk factors. Roughly a quarter to a third of people who present with a first deep vein thrombosis (DVT) or pulmonary embolism turn out to carry Factor V Leiden — a much higher rate than in the general population — which is why it's one of the first things hematologists screen for after an unexplained clot. Carrying it alongside a second thrombophilia mutation (Prothrombin G20210A) or while on estrogen-containing birth control multiplies the risk further, rather than simply adding to it.
Why This Matters for Family Planning
This is the connection most people miss. Estrogen-containing hormonal contraception already raises clotting risk somewhat on its own; adding Factor V Leiden on top compounds it meaningfully, which is one reason OB-GYNs increasingly ask about family history of clots before prescribing combined hormonal birth control. Pregnancy itself is also a naturally hypercoagulable state — clotting risk rises for everyone, and rises further for carriers, particularly in the postpartum period. Knowing your status before you're prescribed a hormonal method or before you conceive gives your doctor the chance to choose a different contraceptive option or add preventive measures (like prophylactic blood thinners around delivery) proactively rather than reactively.
Carrying Factor V Leiden is common and, for most people, never becomes symptomatic. It matters most in combination — with estrogen-based birth control, pregnancy, surgery, long-haul travel, or a second clotting mutation. It's not a diagnosis of a disease; it's a risk factor worth your doctor knowing about before those situations come up.
Should You Get Tested?
If you have a personal or family history of unexplained blood clots, recurrent miscarriage, or you're about to start estrogen-containing birth control and have a family history of clotting problems, this is worth discussing with your doctor directly — targeted clinical thrombophilia panels exist for exactly this reason. Outside of that specific context, Factor V Leiden status is also one of the many data points captured in whole genome sequencing, which means it's already sitting in your raw data if you've been sequenced for other reasons — no separate test required.
Factor V Leiden Is Already in Your Genome
Dante Labs' whole genome sequencing captures thousands of clinically relevant variants — including thrombophilia markers like Factor V Leiden — in a single test you own. Use code GENOME for 10% off.
Get Sequenced with Dante Labs → 10% off with code GENOMEFor more on how genetics intersects with pregnancy planning, see our guide to genetic testing for couples planning a family and our deeper dive on what comes after carrier screening. If medications and genetics are on your mind, our pharmacogenomics guide covers how your genes affect drug response more broadly.